Asset
Aramchol meglumine
Galmed Pharmaceuticals Ltd. Ordinary Shares
Revenue
No revenue reported in loaded filings.
Clinical trials (2)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT06095986 | phase2 | withdrawn | 2025-06-01 | 2026-09-01 | Galmed Pharmaceuticals Ltd | A Study Evaluating the Safety, Tolerability, and Efficacy of Aramchol Meglumine in Primary Sclerosing Cholangitis |
| NCT06502561 | phase1 | completed | 2025-02-15 | 2025-06-15 | Galmed Pharmaceuticals Ltd | Comparing The PK Of Aramchol Meglumine Granules To Aramchol Free Acid Tablets |
FDA applications (0)
This company has no applications containing this asset.